Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 120 Matches

Sulfamethoxazole_MechKiM_V16R1_UniversityOfManchester_20210421
Model Files Publication
https://doi.org/10.1124/jpet.118.251413 Sulfamethoxazole compound file with MechKiM
Search Score: 1
Hydroxychloroquine_V18R1_PekingUniversityThirdHospital_20220209
Model Files Publication
PBPK model of Hydroxychloroquine and its metabolite of Desethyl-hydroxychloroquine. This file is a further development of the file for Hydroxychloroquine (V18R1) also available within this database: In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - PubMed (nih.gov)
Search Score: 1
MefenamicAcid_Dapagliflozin_V15R1_Pfizer_20220726
Model Files Publication
Mefenamic acid and dapagliflozin/healthy volunteer. This workspace simulates the UGT mediated DDI after multiple dose administration of UGT inhibitor mefenamic acid. The workspace shows Dapaglifazin as substrate of UGTA9 and UGT2B7. Mefenamic Acid is used in the inhibitor position and Ki values against UGT1A9 and UGT2B7 are included in the workspace.
Search Score: 1
Rivaroxaban_V17R1_NationalUniversityofSingapore_20200923
Model Files Publication
https://dmd.aspetjournals.org/content/47/11/1291/tab-article-info This workspace was developed to recapitulate the magnitude of drug-drug interaction reported between Rivaroxaban and Verapamil as reported by Greenblatt et al. (https://pubmed.ncbi.nlm.nih.gov/29194698/) Note 1: In Table 1 of the publication the Caco-2 Papp (pH 7.4:7.4) was reported as 8 x 10-6 cm/s; however, the Rivaroxaban file in the workspace is using a Caco-2 Papp (pH 7.4:7.4) of 21.8 x 10-6 cm/s. This Papp is in line with the reported scalar in the EXCEL outputs and the Table 1. The obtained Rivaroxaban plasma concentration time profile is in line with the reported Figure 2C in the publication. Note 2: In Table 1 of the publication, input data for Mech KiM are stated; however, the Rivaroxaban file in the workspace is using a User Input for the renal clearance of 3.1 L/h; while the input data for Mech KiM are included in the compound file, they are not activated within the workspace, which is mimicking a DDI with Verapamil and Norverapamil. Note 3: Bile:micelle parameters were changed from 3.4 to 3.5.
Search Score: 1

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|